Biotech

All Articles

Ascendis' dwarfism medication hits in period 3, intimidates BioMarin

.Ascendis Pharma has actually become a prospective hazard to BioMarin's Voxzogo, mentioning period 3...

Despite ph. 3 skip, Alkeus sees course ahead for eye disease resource

.Though Alkeus Pharmaceuticals' dental eye illness resource neglected to significantly lower geograp...

Kairos goes public along with $6M IPO to money tests of cancer cells medicine

.With a trio of biotechs striking the Nasdaq on Friday, it was very easy to overlook a smaller-scale...

Vaccine and also Keytruda combination successful in squamous cell carcinoma

.Immune system gate inhibitors are the superheroes of cancer cells therapy. Drugs like Bristol Myers...

Cue Biopharma mark time J&ampJ vet as CBO-- Chutes &amp Ladders

.Welcome to this week's Chutes &amp Ladders, our summary of substantial management hirings, firings ...

Regeneron's Opdualag opponent presents 57% reaction price

.Regeneron is actually back with long-lasting follow-up for its own LAG-3 inhibitor and also PD-1 pr...

AstraZeneca posts data on in-house rivals to AbbVie, Pfizer ADCs

.AstraZeneca has shared an early look at the functionality of its internal antibody-drug conjugate (...

iTeos- GSK's TIGIT superstar shows purposeful improvement

.After introducing a stage 3 launch based upon positive midstage outcomes, iTeos and GSK are actuall...

More collaborative FDA can speed up uncommon disease R&ampD: record

.The FDA must be much more open as well as collaborative to discharge a rise in commendations of unu...

Zenas, MBX, Bicara head to Nasdaq in hot day for biotech IPOs

.It is actually an uncommonly hectic Friday for biotech IPOs, along with Zenas BioPharma, MBX as wel...